Dayvigo (Lemborexant) Adolescent Safety: What Parents and Clinicians Need to Know About Ages 12 to 17
A clinician-reviewed guide to lemborexant (Dayvigo) safety in adolescents aged 12 to 17, covering off-label evidence, orexin system development, mental health monitoring, and risk-benefit considerations.
Read clinical review